Synopsis Atenolol is a selective β 1-adrenoceptor antagonist with a duration of activity of at
least 24 hours. The scope of therapeutic use of the drug has been expanded and become …

Background The clinical view of case fatality (CF) from acute myocardial infarction (AMI) in
those reaching the hospital alive is different from the population view. Registration of both …

Mild‐to‐moderate essential hypertension is a major risk factor for stroke and cardiovascular
mortality and morbidity. Morbidity can be reduced significantly by lowering high blood …

The aim of this guideline is to provide recommen? dations to aid primary health care
professionals in their management of patients with chronic stable angina due to coronary …

D de Bono, for the Joint Working Party of the British Cardiac Society and Royal College of
Physicians of London In October 1991 the joint audit committee of the British Cardiac …

Type of study: Descriptive study of trends in the drug therapy for acute myocardial infarction.
Setting: Population‐based register of acute coronary events compiled for the years 1984 to …

Based on selected patient populations, several randomized trials have shown beta blockers
to decrease mortality after acute myocardial infarction (AMI). The purpose of this study was …

Atenolol. a cardio selective~-adrenergic blocker. frequently prescribed in various cardiac
ailments. has not been thoroughly investjgated for its adverse reaction profile in Indian …

Ischemic heart disease is one of the leading causes of mortality worldwide [1]. Management
of patients with stable ischemic heart disease involves risk modification, anti-platelet …

Abstract β-Blockers are known to protect a vulnerable aorta from acute dissection, as well as
reducing the risk of recurrent dissection. This case presentation reports the history of a 60 …